Roman Yelensky

Roman Yelensky

UNVERIFIED PROFILE

Are you Roman Yelensky?   Register this Author

Register author
Roman Yelensky

Roman Yelensky

Publications by authors named "Roman Yelensky"

Are you Roman Yelensky?   Register this Author

74Publications

3973Reads

37Profile Views

Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Trends Immunol 2018 07 8;39(7):536-548. Epub 2018 May 8.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2018.04.005DOI Listing
July 2018

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.

J Clin Pathol 2016 May 23;69(5):403-8. Epub 2015 Oct 23.

Department of Pathology, Albany Medical College, Albany, New York, USA Foundation Medicine, Inc., Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2015-203394DOI Listing
May 2016

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Sci Transl Med 2016 Apr;8(334):334ra53

Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA. Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA. Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aad3001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256931PMC
April 2016

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.

J Natl Cancer Inst 2016 Jan 12;108(1). Epub 2015 Nov 12.

Rady Childrens Hospital, San Diego, CA (VW, JC, DM, HA); Foundation Medicine, Inc., Cambridge, MA (DP, TB, RY, JSR, VAM, PJS, SMA); Albany Medical College, Albany, NY (JSR).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/108/1/djv307.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djv307
Publisher Site
http://dx.doi.org/10.1093/jnci/djv307DOI Listing
January 2016

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

Oncologist 2016 Jan 15;21(1):33-9. Epub 2015 Dec 15.

Foundation Medicine, Inc., Cambridge, Massachusetts, USA; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://www.foundationmedicine.com/wp-content/uploads/2015/12
Web Search
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2015-0241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709208PMC
January 2016

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

Oncologist 2015 Oct 2;20(10):1132-9. Epub 2015 Sep 2.

Foundation Medicine, Inc., Cambridge, Massachusetts, USA; Division of Hematology-Oncology, University of California Irvine, Orange, California, USA; The Ohio State University-James Cancer Hospital, Columbus, Ohio, USA; National Translational Research Group, New York, New York, USA; Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591943PMC
October 2015

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Oncologist 2015 May 16;20(5):499-507. Epub 2015 Apr 16.

Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University of Chicago, Chicago, Illinois, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425384PMC
May 2015

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

Arch Pathol Lab Med 2015 May;139(5):642-9

From the Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York (Drs Ross and Boguniewicz and Ms Sheehan); Research and Development, Foundation Medicine, Inc, Cambridge, Massachusetts (Drs Ross, Wang, Otto, Yelensky, Lipson, Ali, Morosini, Chliemlecki, Elvin, Miller, and Stephens); and the Department of Pathology, University of Indiana School of Medicine, Indianapolis (Dr Badve).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2014-0200-OADOI Listing
May 2015

Multiple gene aberrations and breast cancer: lessons from super-responders.

BMC Cancer 2015 May 29;15:442. Epub 2015 May 29.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1439-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446801PMC
May 2015

RET fusion as a novel driver of medullary thyroid carcinoma.

J Clin Endocrinol Metab 2015 Mar 29;100(3):788-93. Epub 2014 Dec 29.

Departments of Surgical Oncology (E.G.G., J.B., J.E.L., F.M.-B., N.D.P.), Institute of Personalized Cancer Therapy (P.K.-S.N., K.R.S.), Endocrine Neoplasia and Hormonal Disorders (N.L.B., S.G.W., G.J.C.), Bioinformatics and Computational Biology (K.C.), Hematopathology (X.L.), Investigational Cancer Therapeutics (F.M.-B.), Systems Biology (G.B.M.), and Pathology (M.D.W.), University of Texas MD Anderson Cancer Center, Houston, Texas 77030; Foundation Medicine (G.P., R.Y.), Cambridge, Massachusetts 02141; and Integrative Molecular and Biomedical Sciences Graduate Program (H.L., K.L.S.), Baylor College of Medicine, Houston, Texas 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2014-4153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333032PMC
March 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.

BMC Cancer 2015 Feb 18;15:61. Epub 2015 Feb 18.

Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1029-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232PMC
February 2015

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

J Natl Cancer Inst 2014 Dec 8;107(2). Epub 2014 Dec 8.

Department of Oncology (MPG, MMA, JNI), Department of Health Sciences Research (VJS, KRK), and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, SLS, MK, MMA), Mayo Clinic, Rochester, MN; Department of Genetics, University of North Carolina, Chapel Hill, NC (GOS, CMP); Center for Personalized Therapeutics, University of Chicago, Chicago, IL (YN, NJC, MJR); Foundation Medicine Inc., Cambridge, MA (JXS, PJS, VAM, JSR, RY); Novartis Pharmaceuticals Corporation, East Hanover, NJ (DC); Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY (JSR); Division of Hematology/Oncology, Vanderbilt University, Nashville, TN (HG); Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (AMGA, OB); Department Breast Cancer Susceptibility and Pharmacogenomics, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, University Tuebingen, German Cancer Consortium (DKTK) and German Cancer Research (DKTK), Heidelberg, Germany (HB).Current affiliation of H. Gomez: Departamento de Medicina Oncologica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565524PMC
December 2014

Concordance of genomic alterations between primary and recurrent breast cancer.

Mol Cancer Ther 2014 May 7;13(5):1382-9. Epub 2014 Mar 7.

Authors' Affiliations: Departments of Investigational Cancer Therapeutics, Surgical Oncology, Bioinformatics and Computational Biology, Pathology, Systems Biology, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Foundation Medicine, Cambridge, Massachusetts; Albany Medical College, Albany, New York; Fundacion para la Investigacion; Departments of Hematology-Oncology and Pathology, Hospital Clinico Universitario de Valencia; and INCLIVA Biomedical Research Institute, Valencia, Spain.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-13
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-13-0482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348062PMC
May 2014

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Oncologist 2014 Mar 21;19(3):235-42. Epub 2014 Feb 21.

Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA; Foundation Medicine, Inc., Cambridge, Massachusetts, USA; University of Chicago, Chicago, Illinois, USA; The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958461PMC
March 2014

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Cancer Discov 2014 Feb 19;4(2):232-45. Epub 2013 Dec 19.

Departments of 1Medicine, 2Pathology, Microbiology & Immunology, 3Cancer Biology, and 4Biochemistry; 5Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; Departments of 6Cell & Tissue Biology and 7Medicine, University of California, San Francisco, San Francisco, California; 8Foundation Medicine, Cambridge, Massachusetts; 9Oncosalud; and 10Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Perú

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946308PMC
February 2014

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Cancer Res 2013 Dec 11;73(23):6856-64. Epub 2013 Nov 11.

Authors' Affiliations: Department of Oncology, Tel Aviv Sourasky Medical Center; Sackler Faculty of Medicine; The Bioinformatics Unit, Goerge S. Wise Faculty of Life Sciences, Tel Aviv University; Assuta Medical Center, Tel Aviv; Kaplan Medical Center, Rehovot; Oncotest-Teva Pharmaceutical Industries; Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Foundation Medicine, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1197DOI Listing
December 2013

Estimation of the multiple testing burden for genomewide association studies of nearly all common variants.

Genet Epidemiol 2008 May;32(4):381-5

Department of Computer Science, Columbia University, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gepi.20303DOI Listing
May 2008

Evaluating and improving power in whole-genome association studies using fixed marker sets.

Nat Genet 2006 Jun 21;38(6):663-7. Epub 2006 May 21.

Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng1816DOI Listing
June 2006

Efficiency and power in genetic association studies.

Nat Genet 2005 Nov 23;37(11):1217-23. Epub 2005 Oct 23.

Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street, CPZN-6818, Boston, Massachusetts 02114-2790, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ng1669
Publisher Site
http://dx.doi.org/10.1038/ng1669DOI Listing
November 2005